The Pol Beta enzyme repairs damaged DNA, but its activity can hinder cancer treatment by repairing radiation-induced DSBs. Inhibition of Pol Beta activity with natural or synthetic compounds increases cancer cell sensitivity to radiation and chemotherapy. Pol Beta is a promising target for therapeutic modulation in cancer treatment, but further research is needed to identify more potent and specific inhibitors and their clinical applications. Is the molecule effective to this assay?